1 |
Orzelska-górka J, Mikulska J, Wiszniewska A, Biała G. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. IJMS 2022;23:10624. [DOI: 10.3390/ijms231810624] [Reference Citation Analysis]
|
2 |
Li Z, Xue M, Zhao L, Zhou Y, Wu X, Xie X, Lang X, Zhang X. Comorbid major depression in first-episode drug-naïve patients with schizophrenia: Analysis of the Depression in Schizophrenia in China (DISC) study. J Affect Disord 2021;294:33-8. [PMID: 34265669 DOI: 10.1016/j.jad.2021.06.075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Češková E. Treatment options for pharmacoresistant depression in routine clinical practice. Psychiatr pro Praxi 2021;22:138-142. [DOI: 10.36290/psy.2021.030] [Reference Citation Analysis]
|
4 |
Liu R, Fang X, Yu L, Wang D, Wu Z, Guo C, Teng X, Ren J, Zhang C. Gender Differences of Schizophrenia Patients With and Without Depressive Symptoms in Clinical Characteristics. Front Psychiatry 2021;12:792019. [PMID: 35095605 DOI: 10.3389/fpsyt.2021.792019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
5 |
Češková E, Hýža M. Treatment possibilities of pharmaco-resistant schizofrenie in common clinical practice. Psychiatr pro Praxi 2020;21:78-82. [DOI: 10.36290/psy.2020.014] [Reference Citation Analysis]
|